



## Anti-F7 polyclonal antibody (DPAB2199SH)

This product is for research use only and is not intended for diagnostic use.

## PRODUCT INFORMATION

| Antigon | Description  |
|---------|--------------|
| Andaen  | Describition |

Factor VII (F.VII, also known as Stable Factor and Proconvertin)is a vitamin K-dependent glycoprotein produced in the liver. Plasma concentrationof F.VII is normally ~0.5  $\mu$ g/ml (10 nM) in plasma. A deficiency of F.VII is associated with bleeding in a clinical pattern similar to haemophilia, but isinherited as an autosomal recessive

trait. The deficiency can be characterized by a quantitative(low activity and low antigen) or a qualitative (low activity and normal antigen)defect in F.VII function. In its zymogen form F.VII is a single chainmolecule of  $\sim$ 50 kDa. It contains two EGF-like domains and an aminoterminaldomain containing 10  $\gamma$ -carboxyglutamicacid (Gla)

residues. These Gla residues allow F.VII to bind divalent metalions and participate in calcium-dependent binding interactions. F.VII and activatedF.VII (F.VIIa) bind to tissue factor exposed at the site of vascular injury.F.IXa, F.Xa or F.VIIa rapidly activate tissue factorbound F.VII to F.VIIa inthe presence of calcium and phospholipid. Thrombin and F.XIIa are able toactivate F.VII in the fluid phase in the absence of cofactors. The activation of the single chain zymogen F.VII occurs by proteolysis after residue Arg152,resulting in a twochain active serine protease consisting of a 30 kDa heavychain and

an 18 kDa light chain. In complex with tissue factor,phospholipid and calcium, F.VIIa is able to activate F.X and F.IX. FreeF.VIIa in plasma is remarkably stable, but the activity of F.VIIa/TF complexis regulated by Tissue Factor Pathway Inhibitor (TFPI) in the presence of F.Xa,and also by Antithrombin (ATIII) in the presence of heparin.

| Specificity        | Prior toconjugation, this antibody was specific for F.VII as demonstrated byimmunoelectrophoresis and ELISA. |
|--------------------|--|
| Immunogen          | HumanF.VII purified from plasma.   |
| Source/Host        | Sheep  |
| Species Reactivity | Human  |
| Conjugate          | Unconjugated   |
| Size               | 100 μg   |

45-1 Ramsey Road, Shirley, NY 11967, USA

Tel: 1-631-624-4882 Fax: 1-631-938-8221

Email: info@creative-diagnostics.com

© Creative Diagnostics All Rights Reserved

| Buffer       | Phosphate-bufferedsaline containing 1 mg/mL bovine albumin and 0.1% sodium azide (w/v), pH 7.4. |
|--------------|---|
| Preservative | 0.1% Sodium Azide   |
| Storage      | Storeat 2°Cto8°C.   |

## **GENE INFORMATION**

| Gene Name           | F7 coagulationfactor VII (serum prothrombin conversion accelerator) [ Homo sapiens ]  |
|---------------------|---|
| Official Symbol     | F7  |
| Synonyms            | F7; coagulationfactor VII (serum prothrombin conversion accelerator); SPCA; eptacog alfa; proconvertin; FVII coagulation protein; factor VII; F.VII; Stable Factor; Serum prothrombin conversion accelerator; EC 3.4.21.21; OTTHUMP00000018733; OTTHUMP00000018734; EC 3.4.21; Proconvertin; coagulation factor VII |
| Entrez Gene ID      | <u>2155</u>   |
| Protein Refseq      | <u>NP_000122</u>  |
| UniProt ID          | <u>P08709</u>   |
| Chromosome Location | 13q34   |
| Pathway             | BMAL1:CLOCK/NPAS2Activates Gene Expression; Blood Clotting Cascade; Circadian Clock;Complement and Coagulation Cascades; Complement and coagulation cascades;Extrinsic Pathway; Formation of Fibrin Clot (Clotting Cascade); Gammacarboxylationof protein precursors; Hemostasis; Metabolism of proteins            |
| Function            | calcium ion binding;glycoprotein binding; peptidase activity; receptor binding; serine-typeendopeptidase activity; serine-type peptidase activity   |